Feedback
Settings

Settings

Goto Application

339,622 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 33,963
1.2039866BROAD-SPECTRUM MESSENGER RIBONUCLEIC ACID VACCINE AGAINST CHIKUNGUNYA VIRUS DESIGNED BY OPTIMIZING FULL-LENGTH STRUCTURAL PROTEIN SEQUENCE
NL - 27.06.2025
Int.Class C07K 14/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
18Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
 Appl.No 2039866 Applicant Institute of Medical Biology, Chinese Academy of Inventor Shuaiyao Lu
The present invention belongs to the technical field of messenger ribonucleic acid {mRNA} vaccine preparation, and specifically relates to a broad—spectrum mRNA vaccine against Chilrungunya virus {CHECK-') designed by optimizing the full—length structural protein sequence. Specifically, an amino acid sequence of the protein provided by the present invention is shown in SEQ ID HD. 1. The vaccine provided by the present invention has a stronger level of cellular immune response, a higher sustained level of binding antibodies produced after a dose reaches a certain level, and a certain effect on the level of neutralizing antibodies. In a broad—spectrum, the vaccine produced IÜ neutralizing antibodies against pseudoviruses from West Afiican pedigrees, Indian lÜcean pedigrees, and East Central and SouthAfiican pedigrees, with cross—protection.Fig .l
2.20250206788CURCUMIN-PEPTIDE CONJUGATES AND FORMULATIONS THEREOF
US - 26.06.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No 19074778 Applicant John Chancey Inventor Adam J. PAYNE

Disclosed here are compositions comprising a curcuminoid-N-acetyl cysteine (NAC) complex. Also disclosed are methods of preparing a curcuminoid-N-acetyl cysteine (NAC) complex. Also disclosed are methods of treating a subject, the method comprising identifying a subject in need of treatment of a curcumin-related disorder, and administering to the subject a therapeutic composition comprising a curcuminoid-N-acetyl cysteine (NAC) complex as described. Also disclosed are therapeutic compositions comprising a curcuminoid-N-acetyl cysteine (NAC) complex as described and a pharmaceutically acceptable excipient, diluent, or carrier.

3.20250206817METHODS OF MANUFACTURING DIMERIC ANTIBODIES
US - 26.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 18807097 Applicant Medicovestor, Inc. Inventor Seah Lim

This disclosure relates to dimeric immunotherapeutics that comprise two IgGs that are crosslinked with a disulfide bond. The two IgGs may be chimeras of two different heavy chains, in which one heavy chain includes a cysteine mutation that forms the disulfide bond, and the other heavy chain lacks the cysteine mutation. The presence of a cysteine mutation in only one of the heavy chains of an IgG avoids two disulfide bonds between the two IgGs, which increases the accessible orientations between the two crosslinked IgGs, and also avoids the formation of trimers and higher-order oligomers.

4.20250205313NONPOLYMERIZABLE FIBRINOGEN AS AN ANTITHROMBOTIC AGENT
US - 26.06.2025
Int.Class A61K 38/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
36Blood coagulation or fibrinolysis factors
 Appl.No 18989581 Applicant The University of North Carolina at Chapel Hill Inventor Matthew James Flick

This invention relates to methods for inhibiting or reducing the risk of thrombosis or reducing the size and number of thrombi without compromising hemostasis using a nonpolymerizable fibrinogen that is insensitive to thrombin cleavage. Methods and compositions for reducing a required dose or complementing the effect of an antithrombotic agent in the treatment of thrombosis are also provided.

5.20250207094SYSTEMS AND METHODS FOR UPREGULATION OF LOW-DENSITY LIPOPROTEIN RECEPTOR (LDL-R) EXPRESSION
US - 26.06.2025
Int.Class C12N 5/0783
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
 Appl.No 18987823 Applicant Kite Pharma, Inc. Inventor Maolu Li

The present disclosure describes technologies for improving a T cell manufacturing process. Specifically, upregulating low-density lipoprotein receptor (LDL-R) expression on a T cell surface. The described technologies are particularly suitable in manufacturing processes using of non-activated T cells in a transduction step.

6.WO/2025/130972SYNTHETIC METHOD FOR TIRZEPATIDE
WO - 26.06.2025
Int.Class C07K 14/605
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
605Glucagons
 Appl.No PCT/CN2024/140569 Applicant HYBIO PHARMACEUTICAL CO., LTD. Inventor YANG, Peng
The present invention provides a synthetic method for tirzepatide. The method uses three special materials Fmoc-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-OH, Fmoc-Ile-Aib-OH and Boc-Tyr-Aib-OH.
7.WO/2025/133252IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING CEACAM5
WO - 26.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/EP2024/088111 Applicant ABLYNX NV Inventor NIEBEL, Björn
The present technology provides polypeptides that bind to CEACAM5. The present technology also provides nucleic acids, vectors and compositions.
8.WO/2025/133042ACTIVATABLE FUSION PROTEINS AND METHODS OF USE
WO - 26.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/EP2024/087791 Applicant F. HOFFMANN-LA ROCHE AG Inventor BATES, Jack Anthony
The invention provides activatable fusion proteins and methods of using the same. The invention further provides anti-huIL-2 antibodies and methods of using them.
9.WO/2025/133162RECOMBINANT PROTEIN EXPRESSION
WO - 26.06.2025
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/EP2024/087965 Applicant NOVOZYMES A/S Inventor OLSEN, Carsten, Lillelund
The present invention relates to inducible promoters, and to methods of protein production, wherein recombinant cells are cultivated in a cultivation medium comprising acetate. The invention further relates to formulations and compositions obtained with the method of the invention.
10.WO/2025/133132NOVEL ANTI-TFR1 (CD71) ANTIBODIES FOR CANCER TREATMENT
WO - 26.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/EP2024/087923 Applicant INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Inventor LOPEZ, Marc
The present invention relates to an antibody targeting transferrin receptor 1 (TfR1), which binds a transferrin-sensitive conformational active form of TfR1. It also relates to the use of said antibody for cancer treatment.
# -